Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Pharmaceuticals Inc.

www.regeneron.com

Latest From Regeneron Pharmaceuticals Inc.

Keen Kevzara Pricing Will Be Sanofi’s Best Hope After Speedy NICE Nod

A three-month turnaround from approval in Europe for Sanofi’s rheumatoid arthritis drug to recommendation in England is pretty quick. The firm will need to maintain keen pricing in a competitive field.

Immune Disorders Reimbursement

Pipeline Watch: Phase III Progress With Lefamulin, Dupilumab, Patisiran

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Sanofi Ready To Pull The Plug On Regeneron 'Life Support'

Global R&D President Elias Zerhouni said Sanofi has the knowledge and skills it needs to discover antibody drugs internally and it's time to end the perception that Regeneron is keeping Sanofi's R&D humming.

Deals Research & Development

JAK Inhibitors Have Dupixent In Their Sights For Atopic Dermatitis

Analysts predict that Sanofi and Regeneron's Dupixent is going to dominate the severe eczema market but the oral options of Lilly/Incyte's baricitinib and AbbVie's upadacitinib are progressing through the pipeline to make a challenge.

Immune Disorders Dermatology
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Regeneron Pharmaceuticals Inc.
  • Senior Management
  • Leonard S Schleifer, MD, PhD, Pres. & CEO
    Robert E Landry, SVP, Fin. & CFO
    George D Yancopoulos, MD, PhD, Pres. & CSO
    Robert J Terifay, EVP, Commercial
  • Contact Info
  • Regeneron Pharmaceuticals Inc.
    Phone: (914) 847-7000
    777 Old Saw Mill River Rd.
    Tarrytown, NY 10591
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register